Table 2 Summary of treatment-related adverse events.
25 mg (N = 16) | 50 mg (N = 16) | 75 mg (N = 8) | 100 mg (N = 1) | |
|---|---|---|---|---|
Elevated ALT | 3 (18.8%) | 9 (56.3%) | 5 (62.5%) | 0 |
Elevated AST | 3 (18.8%) | 8 (50.0%) | 4 (50.0%) | 0 |
Elevated blood pressure | 4 (25.0%) | 6 (37.5%) | 3 (37.5%) | 0 |
Leucopenia | 1 (6.3%) | 3 (18.8%) | 3 (37.5%) | 0 |
QT interval prolongation | 2 (12.5%) | 4 (25.0%) | 1 (12.5%) | 0 |
Thrombocytopenia | 2 (12.5%) | 1 (6.3%) | 3 (37.5%) | 0 |
Neutropenia | 1 (6.3%) | 3 (18.8%) | 2 (25.0%) | 0 |
Hair colour changes | 0 | 4 (25.0%) | 2 (25.0%) | 0 |
